Why Pediatric Psoriasis Looks Different
Recorded live at the Elevate-Derm summer conference in San Diego, PA Buchi Neita and PA Eileen Cheever open the conversation by noting a gap: pediatric psoriasis isn’t discussed often enough, partly because many medications aren't approved for younger patients. Cheever notes that the clinical exam itself is the first challenge. Pediatric plaques can be thinner and a bit more scaly, with more frequent facial and scalp involvement, pre- and post-auricular disease, and scattered presentations that don't always match what a referring pediatrician has seen on Google or YouTube.
Neita shares a clinical challenge of her own: a roughly four-year-old with facial psoriasis plus groin and genital involvement who had been treated with a host of antifungals by his pediatrician, who assumed candida. When she finally made the diagnosis, the facial disease ran right along his eyelash line, forcing the question of what she would be comfortable prescribing for such a delicate special site. Getting the right diagnosis and finding appropriate therapy for these high-sensitivity locations is, both hosts agree, a recurring hurdle.
Guttate psoriasis also earns attention because of its streptococcal correlation. Cheever even mentions getting a message about strep going through her daughter's daycare right before going on stage. When a guttate presentation shows up, her workup includes asking about chronic ear infections, recent strep, and whether siblings or other family members have been infected. She'll screen with an ASO titer, discuss diagnosis and treatment, and has no problem sending an antibiotic prescription if indicated. Neita adds that strep isn't the only trigger — viral infections, including mono, can be involved — so a thorough history matters.
Knowing When to Escalate Beyond Topicals
The hosts lay out several triggers for moving past topical therapy. Significant body surface area and disease refractory to multiple topicals are the easy calls. But Cheever frames a more nuanced question she keeps in mind: is the topical working from an efficacy standpoint, and is it working within the family dynamic? A regimen that would clear a child in a vacuum — consistent twice-daily application over a large surface area — often collapses under the realities of school, sports, and two different households.
Special sites push the decision too. Scalp involvement, inverse psoriasis, and nail disease function as near-automatic reasons to level up, just as in adults. Both hosts emphasize low-BSA, high-impact areas — disease that peers can see or that holds a child back in sports counts even when the surface area is small.
Psychosocial burden is a major escalation signal. Neita stresses the bullying and shame children experience, and the quiet ways they hide their disease; picking up on any of that is reason to escalate. Cheever also raises comorbidities, noting she hadn't realized how prevalent they are in pediatric psoriasis — cardiovascular disease, metabolic syndrome, dyslipidemia, and diabetes can appear in children just as in adults. She suggests screening, especially where obesity is involved, and warns against overlooking psoriatic arthritis. Neita recounts a case where she tracked a scalp-only patient for years as seborrheic dermatitis before recognizing psoriasis, then realized she had missed psoriatic arthritis entirely until the mother mentioned her son's joint pain and daily ibuprofen.
Shared Decision-Making and Advocating for the Right Drug
When choosing systemic therapy, Cheever starts by eliciting the family’s goals, then steers toward options that fit—considering FDA-approved age ranges and route of administration, oral versus injectable, and dosing frequency. She also probes baseline knowledge with open-ended questions, such as asking what the family already knows about treatment beyond cream, since many families assume psoriasis is treated only with topicals.
Both hosts underscore the need to advocate against payers who try to force off-label use. They point out that methotrexate and adalimumab are not approved for pediatric psoriasis, so pushing those agents as a trial-and-error approach is a weak argument when orals and multiple biologics are approved for ages six and up. Neita's advice is blunt: fight for your patient and write strongly worded letters to get the appropriate, studied agent.
The hosts also describe stepping in as the child's advocate in the room — for example, the eight-to-ten-year-old boy who simply won't apply creams while a parent insists the cream works 'if he would just use it.' Recognizing where a child is developmentally, and that creams aren't a long-term solution, sometimes means advocating for the more convenient, higher-adherence option. Neita draws a parallel to getting a teenage boy with acne onto isotretinoin rather than fighting over topicals.
Needles, Vaccines, and the Family Dynamic
Family logistics complicate care. The hosts describe divorced households, grandparents attending appointments, duplicate creams for two homes, and even a case where separated parents both showed up and police had to be called, leaving a teenager embarrassed and the visit canceled. The practical lesson: figure out what's realistic for this family, not just what works in theory.
For needle fear and injectables, Cheever borrows from her adult playbook — asking whether anyone in the family has experience with injectable medications. With so many adults now on GLP-1s or managing conditions like type 1 diabetes, she finds families more open to injectables than expected, and she frames the conversation positively around infrequent dosing. Both hosts note that if injecting at home becomes a battle, families can come to the clinic for the injection, billed appropriately, with early or end-of-day appointments. They also stress that whoever performs injections in the office should be trained specifically in pediatric injection technique, not just adult.
On vaccines, the co-host explains that standard biologic guidance is to avoid live vaccines, driven by concern that they may blunt the immune response rather than interfere with the vaccine itself. Her personal practice is to hold the biologic for four weeks, vaccinate, then resume — while acknowledging clinicians differ and robust protocols and data are lacking.
What's Available Now and Final Advice
Neita is most excited simply to have options, which she organizes by age. For children six years and older, FDA-approved biologics include risankizumab (now approved down to age six, even below 40 kg, at 55 mg), older TNF options (four years and up), and ixekizumab for 12 years and older at 40 kg or more. Orally, apremilast is indicated down to age six at 20 kg or more. Multiple newer non-steroidal topicals also have lower age ranges, though both hosts want more well-studied options for the youngest patients.
Their closing advice: screen for psoriatic arthritis and examine these children as thoroughly as adults. The co-host urges clinicians to 'put on that cape' and advocate — most of these kids are remarkably healthy and good candidates for systemic therapy, and they only get one childhood. Neita's hero story of a 12-year-old who wanted clear skin for a Disney cruise in six weeks—achieved with a biologic plus topical and a loading dose—shows how the right medication can change a child's life. Start with the patient, weigh medical history and family dynamics, categorize the options, and be especially sensitive to the psychosocial toll, reassuring kids that psoriasis isn't contagious or shameful.